Organovo (ONVO) Competitors $0.37 -0.01 (-2.61%) As of 02/21/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ONVO vs. CTXR, TRAW, ENLV, BCAB, TNXP, LSB, MTEX, SXTP, NXTC, and INABShould you be buying Organovo stock or one of its competitors? The main competitors of Organovo include Citius Pharmaceuticals (CTXR), Traws Pharma (TRAW), Enlivex Therapeutics (ENLV), BioAtla (BCAB), Tonix Pharmaceuticals (TNXP), Lakeshore Biopharma (LSB), Mannatech (MTEX), 60 Degrees Pharmaceuticals (SXTP), NextCure (NXTC), and IN8bio (INAB). These companies are all part of the "pharmaceutical products" industry. Organovo vs. Citius Pharmaceuticals Traws Pharma Enlivex Therapeutics BioAtla Tonix Pharmaceuticals Lakeshore Biopharma Mannatech 60 Degrees Pharmaceuticals NextCure IN8bio Organovo (NASDAQ:ONVO) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations. Does the MarketBeat Community prefer ONVO or CTXR? Citius Pharmaceuticals received 16 more outperform votes than Organovo when rated by MarketBeat users. Likewise, 62.54% of users gave Citius Pharmaceuticals an outperform vote while only 46.56% of users gave Organovo an outperform vote. CompanyUnderperformOutperformOrganovoOutperform Votes19646.56% Underperform Votes22553.44% Citius PharmaceuticalsOutperform Votes21262.54% Underperform Votes12737.46% Do analysts recommend ONVO or CTXR? Citius Pharmaceuticals has a consensus price target of $54.50, suggesting a potential upside of 2,927.78%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Organovo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organovo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Citius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Do institutionals and insiders hold more shares of ONVO or CTXR? 8.2% of Organovo shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 3.7% of Organovo shares are owned by company insiders. Comparatively, 12.1% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, ONVO or CTXR? Organovo has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganovo$110K58.54-$14.67M-$0.85-0.43Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A Is ONVO or CTXR more profitable? Citius Pharmaceuticals has a net margin of 0.00% compared to Organovo's net margin of -10,151.64%. Citius Pharmaceuticals' return on equity of -51.69% beat Organovo's return on equity.Company Net Margins Return on Equity Return on Assets Organovo-10,151.64% -346.26% -187.53% Citius Pharmaceuticals N/A -51.69%-37.60% Does the media refer more to ONVO or CTXR? In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Organovo. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 1 mentions for Organovo. Organovo's average media sentiment score of 1.00 beat Citius Pharmaceuticals' score of 0.00 indicating that Organovo is being referred to more favorably in the media. Company Overall Sentiment Organovo Positive Citius Pharmaceuticals Neutral Which has more risk and volatility, ONVO or CTXR? Organovo has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. SummaryCitius Pharmaceuticals beats Organovo on 13 of the 16 factors compared between the two stocks. Get Organovo News Delivered to You Automatically Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONVO vs. The Competition Export to ExcelMetricOrganovoBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.61M$3.11B$5.84B$9.15BDividend YieldN/A1.55%4.75%3.85%P/E Ratio-0.4329.6426.4919.17Price / Sales58.54329.47435.3770.93Price / CashN/A168.8738.0134.83Price / Book18.453.687.644.62Net Income-$14.67M-$71.72M$3.19B$246.06M7 Day Performance-4.40%-2.50%-2.12%-2.63%1 Month Performance3.25%-0.32%-0.45%-2.16%1 Year Performance-63.47%-12.32%16.26%12.88% Organovo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONVOOrganovo1.1125 of 5 stars$0.37-2.6%N/A-63.1%$6.61M$110,000.00-0.4320Earnings ReportCTXRCitius Pharmaceuticals2.8836 of 5 stars$2.69-0.4%$54.50+1,926.0%-90.6%$23.11MN/A-0.4520Earnings ReportAnalyst ForecastNews CoverageGap UpTRAWTraws Pharma0.5212 of 5 stars$6.21-7.3%N/AN/A$22.67M$230,000.00-0.0417News CoverageGap DownENLVEnlivex Therapeutics3.0716 of 5 stars$1.05+1.0%$9.50+804.8%-68.9%$22.48MN/A-1.0770BCABBioAtla2.7095 of 5 stars$0.46+6.6%$6.00+1,191.4%-83.1%$22.46MN/A-0.2760High Trading VolumeTNXPTonix Pharmaceuticals3.2445 of 5 stars$11.95+4.5%$5,350.00+44,669.9%-99.2%$22.35M$7.77M0.0050Gap UpLSBLakeshore BiopharmaN/A$2.40-0.4%N/AN/A$22.34M$80.82M0.00773Gap DownMTEXMannatech0.5397 of 5 stars$11.80+12.0%N/A+27.8%$22.18M$131.96M-14.57250Analyst ForecastGap UpSXTP60 Degrees Pharmaceuticals1.0336 of 5 stars$0.59-5.6%N/A+45.2%$21.60M$250,000.00-0.063Analyst ForecastNews CoverageNXTCNextCure4.0526 of 5 stars$0.76+4.5%$4.00+428.2%-55.9%$21.21MN/A-0.3690INABIN8bio3.7383 of 5 stars$0.29-10.0%$7.75+2,565.1%-73.6%$21.08MN/A-0.3920Gap DownHigh Trading Volume Related Companies and Tools Related Companies Citius Pharmaceuticals Competitors Traws Pharma Competitors Enlivex Therapeutics Competitors BioAtla Competitors Tonix Pharmaceuticals Competitors Lakeshore Biopharma Competitors Mannatech Competitors 60 Degrees Pharmaceuticals Competitors NextCure Competitors IN8bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ONVO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organovo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONVO Stock Alerts